5lbs: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==structural basis of Zika and Dengue virus potent antibody cross-neutralization== | ==structural basis of Zika and Dengue virus potent antibody cross-neutralization== | ||
<StructureSection load='5lbs' size='340' side='right' caption='[[5lbs]], [[Resolution|resolution]] 2.41Å' scene=''> | <StructureSection load='5lbs' size='340' side='right'caption='[[5lbs]], [[Resolution|resolution]] 2.41Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5lbs]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5LBS OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5LBS FirstGlance]. <br> | <table><tr><td colspan='2'>[[5lbs]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Zikv Zikv]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5LBS OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5LBS FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4uta|4uta]], [[4utb|4utb]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4uta|4uta]], [[4utb|4utb]]</td></tr> | ||
| Line 17: | Line 17: | ||
</div> | </div> | ||
<div class="pdbe-citations 5lbs" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5lbs" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Antibody 3D structures|Antibody 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Human]] | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: | [[Category: Zikv]] | ||
[[Category: | [[Category: Barba-Spaeth, G]] | ||
[[Category: Rey, F A]] | |||
[[Category: Rouvinski, A]] | |||
[[Category: Vaney, M C]] | |||
[[Category: Broadly neutralizing antibody]] | [[Category: Broadly neutralizing antibody]] | ||
[[Category: Immune system-viral protein]] | [[Category: Immune system-viral protein]] | ||
[[Category: Immune system-viral protein complex]] | [[Category: Immune system-viral protein complex]] | ||
[[Category: Zika virus]] | [[Category: Zika virus]] | ||
Revision as of 09:01, 12 June 2019
structural basis of Zika and Dengue virus potent antibody cross-neutralizationstructural basis of Zika and Dengue virus potent antibody cross-neutralization
Structural highlights
Publication Abstract from PubMedZika virus is a member of the flavivirus genus that had not been associated with severe disease in humans until the recent outbreaks, when it was linked to microcephaly in newborns in Brazil and to Guillain-Barre syndrome in adults in French Polynesia. Zika virus is related to dengue virus, and we report here that a category of antibodies isolated from dengue patients and targeting a conformational epitope potently neutralize Zika virus. The crystal structure of two of these antibodies in complex with the envelope protein of Zika virus reveals the details of a conserved epitope, which is also the site of interaction of the envelope protein dimer with the precursor prM protein during virus maturation. Comparison of the Zika and dengue virus immunocomplexes provides a lead for rational, epitope-focused design of a universal vaccine capable of eliciting potent cross-neutralizing antibodies to protect against Zika and dengue viruses simultaneously. Structural basis of potent Zika-dengue virus antibody cross-neutralization.,Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Simon-Loriere E, Sakuntabhai A, Cao-Lormeau VM, Haouz A, England P, Stiasny K, Mongkolsapaya J, Heinz FX, Screaton GR, Rey FA Nature. 2016 Jun 23. doi: 10.1038/nature18938. PMID:27338953[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||